Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Huda Y. Zoghbi

At a glance: Huda Y. Zoghbi is Director at Regeneron Pharmaceuticals (REGN). Their latest SEC Form 4, filed Nov 5, 2026, reported a sale of $6.7M. On file: 0 purchase lines ($0) and 14 sale lines ($9.1M).

Disclosed holdings: about $1.6M of REGN stock: 1,703 shares reported on their latest Form 4 (filed Nov 5, 2026), valued at the Nov 19, 2026 close of $932.53. This counts only REGN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Regeneron Pharmaceuticals, Inc. (REGN)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $9.1M

Huda Y. Zoghbi's InsiderPrint

14 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.

InsiderPrint of Huda Y. Zoghbi: 14 trades, 2026 to 20262026: 0 buys, 14 sales

Reading this print: Almost only sells, trading about 14 times a year, typically $163K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.

  • Bump outward: a purchase (0)
  • Dent inward: a sale (14)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Steven A. MarkelDirector · MKL · 99% match
  2. Harold H. ShlevinDirector · GALT · 99% match
  3. Octavio EspinozaCFO · LGND · 99% match
  4. Chad Michael WhalenEvp, Worldwide Sales · FFIV · 99% match
  5. Daniel Stanley PerottiCFO · PFSI · 99% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 5SEC REGNRegeneron Pharmaceuticals, Inc. Sell 6,9392,203 held (−76%) $970.42 $6.7M -3.9%
Nov 5SEC REGNRegeneron Pharmaceuticals, Inc. Sell 5001,703 held (−23%) $971.06 $486K -4.0%
Aug 12SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 8001,703 held (−32%) $800.00 $640K +16.6%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 493,292 held (−1%) $774.68 $38K +20.4%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 503,242 held (−2%) $775.50 $39K +20.2%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 533,189 held (−2%) $778.47 $41K +19.8%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 2082,981 held (−7%) $779.55 $162K +19.6%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 3312,650 held (−11%) $780.45 $258K +19.5%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 2092,441 held (−8%) $781.28 $163K +19.4%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 2982,143 held (−12%) $782.10 $233K +19.2%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 2201,923 held (−10%) $783.29 $172K +19.1%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 1601,763 held (−8%) $784.45 $126K +18.9%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 561,707 held (−3%) $785.61 $44K +18.7%
Feb 23SEC REGNRegeneron Pharmaceuticals, Inc. Sell Plan 41,703 held (−0%) $790.00 $3K +18.0%
  • Sell

    Director Huda Y Zoghbi sold $6.7M of REGN at $970.42 — cuts the stake by 76%.

  • Sell

    Director Huda Y Zoghbi sold $640K of REGN at $800.00 — cuts the stake by 32%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Huda Y Zoghbi sold $38K of REGN at $774.68 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Huda Y Zoghbi sold $39K of REGN at $775.50 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Huda Y Zoghbi sold $41K of REGN at $778.47 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Huda Y Zoghbi sold $162K of REGN at $779.55 — pre-scheduled 10b5-1 plan sale.

Follow Huda Y. Zoghbi

Get one email when Huda Y. Zoghbi files a new purchase or sale. Free.

At most one email a day about Huda Y. Zoghbi, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.